Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 99

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 99
---
 333-280796). In a concurrent
private placement, the Company also issued to the investors unregistered warrants (the “January 2025 Warrants”) to purchase
up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable
upon issuance, or January 30, 2025, and expire twenty-four months from the date of issuance, or January 30, 2027. The registered direct
offering and concurrent private placement (together, the “January 2025 Offering”) closed on January 30, 2025, resulting in
net proceeds to the Company of approximately $804,346, after deducting the placement agent fees and other offering expenses paid by the
Company.

As compensation for acting as the placement agent
for the January 2025 Offering, in addition to certain cash fees, the Company issued H.C. Wainwright & Co., LLC (the “Placement
Agent”) warrants to purchase up to 15,325 shares of common stock at an exercise price of $6.382 (the “January 2025 Agent Warrants”).
The January 2025 Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.

February 2025 Offering

On February 5, 2025, the Company entered into
a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering
priced at-the-market under the rules of Nasdaq, an aggregate of 300,700 shares of the Company’s common stock at a purchase price
of $3.575 per share. In a concurrent private placement, the Company separately issued to the investors unregistered warrants to purchase
up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share (the “February 2025 Warrants”).
The February 2025 Warrants were immediately exercisable upon issuance and expire twenty-four months from the date of issuance. The registered
direct offering and concurrent private placement (together, the “February 2025 Offering”) closed on February 6, 2025, resulting
in net proceeds to the Company of approximately $908,627, after deducting the placement agent fees and other offering expenses paid by
the Company.

As compensation for acting as the placement agent
for the February 2025 Offering, in addition to certain